Insulin resistance and Parkinson's disease: A new target for disease modification?

Progress in Neurobiology

Volumn 145-146, Issue , 2016, Pages 98-120

  Athauda, D ^a   Foltynie, T ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Disease modification; Insulin resistance; Neurodegeneration; Parkinson's disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA SYNUCLEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; PROTEIN KINASE B; ANTIDIABETIC AGENT;

AUTOPHAGY; BRAIN; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MEMORY; MITOCHONDRION; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM;

ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PARKINSON DISEASE;

EID: 84992383185     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2016.10.001     Document Type: Review

References (359)

1. Abdelsalam, R.M., Safar, M.M., Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NF(B and Nrf2-antioxidant signaling pathways. J. Neurochem. 133 (2015), 700–707, 10.1111/jnc.13087.
2. Alvarez, E., Martínez, M.D., Roncero, I., Chowen, J.A., García-Cuartero, B., Gispert, J.D., Sanz, C., Vázquez, P., Maldonado, A., de Cáceres, J., Desco, M., Pozo, M.A., Blázquez, E., The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92 (2005), 798–806, 10.1111/j.1471-4159.2004.02914.x.
3. Ansorge, S., Nordhoff, K., Bank, U., Heimburg, A., Julius, H., Breyer, D., Thielitz, A., Reinhold, D., Täger, M., Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol. Chem. 392 (2011), 153–168, 10.1515/BC.2011.008.
4. Arnold, S.E., Lucki, I., Brookshire, B.R., Carlson, G.C., Browne, C.A., Kazi, H., Bang, S., Choi, B.-R., Chen, Y., McMullen, M.F., Kim, S.F., High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol. Dis. 67 (2014), 79–87, 10.1016/j.nbd.2014.03.011.
5. Ashpole, N.M., Sanders, J.E., Hodges, E.L., Yan, H., Sonntag, W.E., Growth hormone, insulin-like growth factor-1 and the aging brain. Exp. Gerontol. 68 (2015), 76–81, 10.1016/j.exger.2014.10.002.
6. Athauda, D., Foltynie, T., The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11 (2014), 25–40, 10.1038/nrneurol.2014.226.
7. Athauda, D., Foltynie, T., The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov. Today 21 (2016), 802–818, 10.1016/j.drudis.2016.01.013.
8. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., 2013. Exenatide and the treatment of patients with Parkinson ’ s disease 123. 10.1172/JCI68295.2730.
9. Aviles-Olmos, I., Limousin, P., Lees, A., Foltynie, T., Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136 (2013), 374–384, 10.1093/brain/aws009.
10. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Fmedsci, P.E., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson's disease. J. Parkinsons. Dis., 2014, 10.3233/JPD-140364.
11. El Zyadi, A., Zigmond, M.J., Smith, A.D., IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases. Exp. Brain Res. 234 (2016), 1863–1873, 10.1007/s00221-016-4572-1.
12. Azoulay, L., Yin, H., Filion, K.B., Assayag, J., Majdan, A., Pollak, M.N., Suissa, S., The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ, 344, 2012, e3645.
13. Azoulay, L., Filion, K.B., Platt, R.W., Dahl, M., Dormuth, C.R., Clemens, K.K., Durand, M., Juurlink, D.N., Targownik, L.E., Turin, T.C., Paterson, J.M., Ernst, P., Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, 352, 2016.
14. Béraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., Federoff, H.J., Shimoji, M., Mhyre, T.R., Maguire-Zeiss, K.A., Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein. J. Neuroimmune Pharmacol. 8 (2013), 94–117, 10.1007/s11481-012-9401-0.
15. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157, 10.1053/j.gastro.2007.03.054.
16. Baker, L.D., Cross, D.J., Minoshima, S., Belongia, D., Watson, G.S., Craft, S., Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68 (2011), 51–57, 10.1001/archneurol.2010.225.
17. Bartels, A.L., Willemsen, A.T.M., Doorduin, J., de Vries, E.F.J., Dierckx, R.A., Leenders, K.L., [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat. Disord. 16 (2010), 57–59, 10.1016/j.parkreldis.2009.05.005.
18. Baskin, D.G., Wilcox, B.J., Figlewicz, D.P., Dorsa, D.M., Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 11 (1988), 107–111.
19. Bassil, F., Fernagut, P.-O., Bezard, E., Meissner, W.G.T. for disease modifi, 2014. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disocation?. Prog. Neurobiol., 2014, 10.1016/j.pneurobio.2014.02.005.
20. Bassil, F., Canron, M., Vital, A., Bezard, E., Fernagut, P., Meissner, W., 2015. Brain insulin resistance in Parkinson's disease and Multiple System Atrophy. Submitted.
21. Bauer, B., Hartz, A.M.S., Miller, D.S., Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol. 71 (2007), 667–675, 10.1124/mol.106.029512.
22. Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., Porter, L.E., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439, 10.1016/S0140-6736(10)60590-9.
23. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., Wikström, L., Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338, 10.1002/jnr.21483.
24. Biessels, G.J., Reagan, L.P., Hippocampal insulin resistance and cognitive dysfunction. Nat. Rev. Neurosci. 16 (2015), 660–671, 10.1038/nrn4019.
25. Blázquez, E., Velázquez, E., Hurtado-Carneiro, V., Ruiz-Albusac, J.M., Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front. Endocrinol. (Lausanne)., 5, 2014, 161, 10.3389/fendo.2014.00161.
26. Blüher, M., Kahn, B.B., Kahn, C.R., Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003), 572–574, 10.1126/science.1078223.
27. Blandini, F., Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 8 (2013), 189–201, 10.1007/s11481-013-9435-y.
28. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., De Felice, F.G., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J. Clin. Invest. 122 (2012), 1339–1353, 10.1172/JCI57256.
29. Borghammer, P., Chakravarty, M., Jonsdottir, K.Y., Sato, N., Matsuda, H., Ito, K., Arahata, Y., Kato, T., Gjedde, A., Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct. Funct. 214 (2010), 303–317, 10.1007/s00429-010-0246-0.
30. Bosco, D., Plastino, M., Cristiano, D., Colica, C., Ermio, C., De Bartolo, M., Mungari, P., Fonte, G., Consoli, D., Consoli, A., Fava, A., Dementia is associated with insulin resistance in patients with Parkinson's disease. J. Neurol. Sci. 315 (2012), 39–43, 10.1016/j.jns.2011.12.008.
31. Bouchard, T.P., Malykhin, N., Martin, W.R.W., Hanstock, C.C., Emery, D.J., Fisher, N.J., Camicioli, R.M., Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol. Aging 29 (2008), 1027–1039, 10.1016/j.neurobiolaging.2007.02.002.
32. Boura-Halfon, S., Zick, Y., Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 296 (2009), E581–91, 10.1152/ajpendo.90437.2008.
33. Braatz, E.M., Coleman, R.A., A mathematical model of insulin resistance in Parkinson's disease. Comput. Biol. Chem. 56 (2015), 84–97, 10.1016/j.compbiolchem.2015.04.003.
34. Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D.T., Smeeth, L., Douglas, I., Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med., 12, 2015, e1001854, 10.1371/journal.pmed.1001854.
35. Brundin, P., Barker, R.A., Conn, P.J., Dawson, T.M., Kieburtz, K., Lees, A.J., Schwarzschild, M.A., Tanner, C.M., Isaacs, T., Duffen, J., Matthews, H., Wyse, R.K.H., Linked clinical trials?the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J. Parkinsons. Dis. 3 (2013), 231–239, 10.3233/JPD-139000.
36. Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H., Zychma, M., Blonde, L., LEAD-6 Study Group, 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (London, England) 374 (2009), 39–47, 10.1016/s0140-6736(09)60659-0.
37. Caccamo, A., Majumder, S., Richardson, A., Strong, R., Oddo, S., Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285 (2010), 13107–13120, 10.1074/jbc.M110.100420.
38. Calabresi, P., Castrioto, A., Di Filippo, M., Picconi, B., New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet. Neurol. 12 (2013), 811–821, 10.1016/S1474-4422(13)70118-2.
39. Canal, M., Romaní-Aumedes, J., Martín-Flores, N., Pérez-Fernández, V., Malagelada, C., RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front. Cell. Neurosci., 8, 2014, 313, 10.3389/fncel.2014.00313.
40. Cao, L., Li, D., Feng, P., Li, L., Xue, G.-F., Li, G., Hölscher, C., A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport 27 (2016), 384–391, 10.1097/WNR.0000000000000548.
41. Carlesimo, G.A., Piras, F., Assogna, F., Pontieri, F.E., Caltagirone, C., Spalletta, G., Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 78 (2012), 1939–1945, 10.1212/WNL.0b013e318259e1c5.
42. Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., Torres-Aleman, I., Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002), 1390–1397, 10.1038/nm793.
43. Castellani, R., Smith, M.A., Richey, P.L., Perry, G., Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 737 (1996), 195–200.
44. Cereda, E., Barichella, M., Cassani, E., Caccialanza, R., Pezzoli, G., Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78 (2012), 1507–1511, 10.1212/WNL.0b013e3182553cc9.
45. Ceriello, A., Sportiello, L., Rafaniello, C., Rossi, F., DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin. Drug Saf. 13:Suppl. 1 (2014), S57–68, 10.1517/14740338.2014.944862.
46. Chang, K.L., Ho, P.C., P-glycoprotein (P-gp) efflux limits brain penetration of pioglitazone and stereoisomer of pioglitazone is a better brain penetrant. Alzheimer's Dement, 9, 2013, P892, 10.1016/j.jalz.2013.08.260.
47. Chang, K.L., Pee, H.N., Yang, S., Ho, P.C., Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease. Sci. Rep., 5, 2015, 9000, 10.1038/srep09000.
48. Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y.-D., Ma, T., Thompson, R.C., Zhao, Y., Smith, L., Gasparini, L., Luo, Z., Xu, H., Liao, F.-F., Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3907–3912, 10.1073/pnas.0807991106.
49. Chen, J., Guan, Z., Wang, L., Song, G., Ma, B., Wang, Y., Meta-analysis: overweight, obesity, and Parkinson's disease. Int. J. Endocrinol., 2014, 2014, 203930, 10.1155/2014/203930.
50. Cheng, C.M., Tseng, V., Wang, J., Wang, D., Matyakhina, L., Bondy, C.A., Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146 (2005), 5086–5091, 10.1210/en.2005-0063.
51. Cheng, Z., Tseng, Y., White, M.F., Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21 (2010), 589–598, 10.1016/j.tem.2010.06.005.
52. Chiu, S.-L., Chen, C.-M., Cline, H.T., Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58 (2008), 708–719, 10.1016/j.neuron.2008.04.014.
53. Choi, J.-Y., Jang, E.-H., Park, C.-S., Kang, J.-H., Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 38 (2005), 806–816, 10.1016/j.freeradbiomed.2004.12.008.
54. Choi, J.-S., Park, C., Jeong, J.-W., AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem. Biophys. Res. Commun. 391 (2010), 147–151, 10.1016/j.bbrc.2009.11.022.
55. Clark, J., Reddy, S., Zheng, K., Betensky, R.A., Simon, D.K., Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med. Genet., 12, 2011, 69, 10.1186/1471-2350-12-69.
56. Colca, J.R., McDonald, W.G., Waldon, D.J., Leone, J.W., Lull, J.M., Bannow, C.A., Lund, E.T., Mathews, W.R., Identification of a novel mitochondrial protein (mitoNEET) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286 (2004), E252–E260, 10.1152/ajpendo.00424.2003.
57. Colca, J.R., McDonald, W.G., Cavey, G.S., Cole, S.L., Holewa, D.D., Brightwell-Conrad, A.S., Wolfe, C.L., Wheeler, J.S., Coulter, K.R., Kilkuskie, P.M., Gracheva, E., Korshunova, Y., Trusgnich, M., Karr, R., Wiley, S.E., Divakaruni, A.S., Murphy, A.N., Vigueira, P.A., Finck, B.N., Kletzien, R.F., Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One, 8, 2013, e61551, 10.1371/journal.pone.0061551.
58. Colca, J.R., VanderLugt, J.T., Adams, W.J., Shashlo, A., McDonald, W.G., Liang, J., Zhou, R., Orloff, D.G., Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin. Pharmacol. Ther. 93 (2013), 352–359, 10.1038/clpt.2013.10.
59. Compta, Y., Parkkinen, L., O'Sullivan, S.S., Vandrovcova, J., Holton, J.L., Collins, C., Lashley, T., Kallis, C., Williams, D.R., de Silva, R., Lees, A.J., Revesz, T., Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 134 (2011), 1493–1505.
60. Compta, Y., Parkkinen, L., Kempster, P., Selikhova, M., Lashley, T., Holton, J.L., Lees, A.J., Revesz, T., The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener. Dis. 13 (2014), 154–156, 10.1159/000354670.
61. Consoli, A., Formoso, G., Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. Diabetes. Obes. Metab. 15 (2013), 967–977, 10.1111/dom.12101.
62. Consoli, A., Formoso, G., Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin. Drug Saf. 14 (2015), 207–218, 10.1517/14740338.2015.987122.
63. Corona, J.C., Duchen, M.R., PPARγ and PGC-1α as therapeutic targets in Parkinson's. Neurochem. Res. 40 (2015), 308–316, 10.1007/s11064-014-1377-0.
64. Corona, J.C., Duchen, M.R., PPARγ and PGC-1α as therapeutic targets in Parkinson's. Neurochem. Res. 40 (2015), 308–316, 10.1007/s11064-014-1377-0.
65. Corona, J.C., de Souza, S.C., Duchen, M.R., PPAR(activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp. Neurol. 253 (2014), 16–27, 10.1016/j.expneurol.2013.12.012.
66. Costa, C., Sgobio, C., Siliquini, S., Tozzi, A., Tantucci, M., Ghiglieri, V., Di Filippo, M., Pendolino, V., de Iure, A., Marti, M., Morari, M., Spillantini, M.G., Latagliata, E.C., Pascucci, T., Puglisi-Allegra, S., Gardoni, F., Di Luca, M., Picconi, B., Calabresi, P., Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 135 (2012), 1884–1899, 10.1093/brain/aws101.
67. Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S.R., Green, P.S., Leverenz, J., Cross, D., Gerton, B., Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69 (2012), 29–38, 10.1001/archneurol.2011.233.
68. Cunningham, C., Hennessy, E., Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers. Res. Ther., 7, 2015, 33, 10.1186/s13195-015-0117-2.
69. D'Amelio, M., Ragonese, P., Callari, G., Di Benedetto, N., Palmeri, B., Terruso, V., Salemi, G., Famoso, G., Aridon, P., Savettieri, G., Diabetes preceding Parkinson's disease onset. A case-control study. Parkinsonism Relat. Disord. 15 (2009), 660–664, 10.1016/j.parkreldis.2009.02.013.
70. D'Amico, M., Di Filippo, C., Marfella, R., Abbatecola, A.M., Ferraraccio, F., Rossi, F., Paolisso, G., Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 45 (2010), 202–207, 10.1016/j.exger.2009.12.004.
71. Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., Ferrer, I., Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64 (2005), 816–830.
72. Darsalia, V., Larsson, M., Lietzau, G., Nathanson, D., Nyström, T., Klein, T., Patrone, C., Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor. Diabetes, Obes. Metab. 18 (2016), 537–541, 10.1111/dom.12641.
73. De Felice, F.G., Lourenco, M.V., Ferreira, S.T., How does brain insulin resistance develop in Alzheimer's disease?. Alzheimers. Dement. 10 (2014), S26–S32, 10.1016/j.jalz.2013.12.004.
74. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B., Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004), 494–501.
75. Devaskar, S.U., Giddings, S.J., Rajakumar, P.A., Carnaghi, L.R., Menon, R.K., Zahm, D.S., Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 269 (1994), 8445–8454.
76. Dineley, K.T., Jahrling, J.B., Denner, L., Insulin resistance in Alzheimer's disease. Neurobiol. Dis. 72:Pt A (2014), 92–103, 10.1016/j.nbd.2014.09.001.
77. Dobbs, R.J., Charlett, A., Purkiss, A.G., Dobbs, S.M., Weller, C., Peterson, D.W., Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100 (1999), 34–41.
78. Driver, J.A., Smith, A., Buring, J.E., Gaziano, J.M., Kurth, T., Logroscino, G., Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31 (2008), 2003–2005, 10.2337/dc08-0688.
79. Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S., Buse, J.B., Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33 (2010), 428–433, 10.2337/dc09-1499.
80. Drucker, D.J., Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 12 (2003), 87–100, 10.1517/13543784.12.1.87.
81. Duarte, A.I., Moreira, P.I., Oliveira, C.R., 2012: Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res., 38401, 2012, 7, 10.1155/2012/384017.
82. Duarte, I.A., Candeias, E., Correia, S.C., Santos, R.X., Carvalho, C., Cardoso, S., Plácido, A., Santos, M.S., Oliveira, C.R., Moreira, P.I., Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim. Biophys. Acta 1832 (2013), 527–541, 10.1016/j.bbadis.2013.01.008.
83. Duca, F.A., Côté, C.D., Rasmussen, B.A., Zadeh-Tahmasebi, M., Rutter, G.A., Filippi, B.M., Lam, T.K.T., Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 21 (2015), 506–511, 10.1038/nm.3787.
84. Duka, T., Duka, V., Joyce, J.N., Sidhu, A., Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 23 (2009), 2820–2830, 10.1096/fj.08-120410.
85. Dunn, L., Allen, G.F., Mamais, A., Ling, H., Li, A., Duberley, K.E., Hargreaves, I.P., Pope, S., Holton, J.L., Lees, A., Heales, S.J., Bandopadhyay, R., Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol. Aging 35 (2014), 1111–1115, 10.1016/j.neurobiolaging.2013.11.001.
86. Ebert, A.D., Beres, A.J., Barber, A.E., Svendsen, C.N., Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp. Neurol. 209 (2008), 213–223, 10.1016/j.expneurol.2007.09.022.
87. Ebrahim, A.S., Ko, L.-W., Yen, S.-H., Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein. Neurosci. Lett. 473 (2010), 120–125, 10.1016/j.neulet.2010.02.034.
88. Escribano, L., Simón, A.-M., Pérez-Mediavilla, A., Salazar-Colocho, P., Del Río, J., Frechilla, D., Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 379 (2009), 406–410, 10.1016/j.bbrc.2008.12.071.
89. Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., Frechilla, D., Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35 (2010), 1593–1604, 10.1038/npp.2010.32.
90. Fehm, H.L., Kern, W., Peters, A., The selfish brain: competition for energy resources. Prog. Brain Res. 153 (2006), 129–140, 10.1016/S0079-6123(06)53007-9.
91. Ferreira, S.T., Clarke, J.R., Bomfim, T.R., De Felice, F.G., Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's Dement. 10 (2014), S76–S83, 10.1016/j.jalz.2013.12.010.
92. Ferwana, M., Firwana, B., Hasan, R., Al-Mallah, M.H., Kim, S., Montori, V.M., Murad, M.H., Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet. Med. 30 (2013), 1026–1032, 10.1111/dme.12144.
93. Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S.H., Smiley, D.L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D.J., Pfluger, P.T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J.B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R.D., Tschöp, M.H., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013, 209ra151, 10.1126/scitranslmed.3007218.
94. Finan, B., Yang, B., Ottaway, N., Smiley, D.L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K.M., Fischer, K., Campbell, J.E., Sandoval, D., Seeley, R.J., Bleicher, K., Uhles, S., Riboulet, W., Funk, J., Hertel, C., Belli, S., Sebokova, E., Conde-Knape, K., Konkar, A., Drucker, D.J., Gelfanov, V., Pfluger, P.T., Müller, T.D., Perez-Tilve, D., DiMarchi, R.D., Tschöp, M.H., A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21 (2015), 27–36, 10.1038/nm.3761.
95. Foltynie, T., Brayne, C.E.G., Robbins, T.W., Barker, R.A., The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127 (2004), 550–560, 10.1093/brain/awh067.
96. Freiherr, J., Hallschmid, M., Frey, W.H., Brünner, Y.F., Chapman, C.D., Hölscher, C., Craft, S., De Felice, F.G., Benedict, C., Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27 (2013), 505–514, 10.1007/s40263-013-0076-8.
97. Freude, S., Hettich, M.M., Schumann, C., Stöhr, O., Koch, L., Köhler, C., Udelhoven, M., Leeser, U., Müller, M., Kubota, N., Kadowaki, T., Krone, W., Schröder, H., Brüning, J.C., Schubert, M., Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23 (2009), 3315–3324, 10.1096/fj.09-132043.
98. Gallegos, S., Pacheco, C., Peters, C., Opazo, C.M., Aguayo, L.G., Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front. Neurosci., 9, 2015, 59, 10.3389/fnins.2015.00059.
99. Gao, C., Liu, Y., Jiang, Y., Ding, J., Li, L., Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model. Brain Pathol. 24 (2014), 261–269, 10.1111/bpa.12116.
100. Gao, S., Duan, C., Gao, G., Wang, X., Yang, H., Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int. J. Biochem. Cell Biol. 64 (2015), 25–33, 10.1016/j.biocel.2015.03.006.
101. Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S.B., Rodell, A.B., Braendgaard, H., Gottrup, H., Schacht, A., Brock, B., Rungby, J., In Alzheimerøs disease, six-month treatment with GLP-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front. Aging Neurosci., 2016, 10.3389/fnagi.2016.00108.
102. Geldmacher, D.S., Fritsch, T., McClendon, M.J., Landreth, G., A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol. 68 (2011), 45–50, 10.1001/archneurol.2010.229.
103. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Hölscher, C., Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33 (2012), 265–276, 10.1016/j.neurobiolaging.2010.02.014.
104. Gentilella, R., Bianchi, C., Rossi, A., Rotella, C.M., Exenatide: a review from pharmacology to clinical practice. Diabetes. Obes. Metab. 11 (2009), 544–556, 10.1111/j.1463-1326.2008.01018.x.
105. Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z., Ahmadiani, A., Insulin in the brain: sources, localization and functions. Mol. Neurobiol. 47 (2013), 145–171, 10.1007/s12035-012-8339-9.
106. Ghosh, A., Roy, A., Liu, X., Kordower, J.H., Mufson, E.J., Hartley, D.M., Ghosh, S., Mosley, R.L., Gendelman, H.E., Pahan, K., Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 18754–18759, 10.1073/pnas.0704908104.
107. Ghosh, S., Patel, N., Rahn, D., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D., Wang, K.X., Swerdlow, R.H., The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol. Pharmacol. 71 (2007), 1695–1702, 10.1124/mol.106.033845.
108. Godau, J., Knauel, K., Weber, K., Brockmann, K., Maetzler, W., Binder, G., Berg, D., Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch. Neurol. 68 (2011), 925–931, 10.1001/archneurol.2011.129.
109. Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A.M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, U., Sawchak, S., Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30 (2010), 131–146, 10.1159/000318845.
110. Goldin, M., Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons [WWW Document]. Eur. J. Neurosci., 2003 URL http://www.ncbi.nlm.nih.gov/pubmed/?term=Goldin,M.,+Segal,M.,+2003.+Protein+kinase+C+and+ERK+involvement+in+dendritic+spine+plas-+ticity (accessed 8.27.15).
111. Golpich, M., Amini, E., Hemmati, F., Ibrahim, N.M., Rahmani, B., Mohamed, Z., Raymond, A.A., Dargahi, L., Ghasemi, R., Ahmadiani, A., Glycogen synthase kinase-3 beta (GSK-3β) signaling: implications for Parkinson's disease. Pharmacol. Res. 97 (2015), 16–26, 10.1016/j.phrs.2015.03.010.
112. Gonzales, M.M., Tarumi, T., Eagan, D.E., Tanaka, H., Vaghasia, M., Haley, A.P., Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations. Psychosom. Med. 74 (2012), 691–698, 10.1097/PSY.0b013e31825ff1de.
113. Grahame Hardie, D., AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J. Intern. Med. 276 (2014), 543–559, 10.1111/joim.12268.
114. Greene, L.A., Levy, O., Malagelada, C., Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell. Mol. Neurobiol. 31 (2011), 969–978, 10.1007/s10571-011-9671-8.
115. Griffin, R.J., Moloney, A., Kelliher, M., Johnston, J.A., Ravid, R., Dockery, P., O'Connor, R., O'Neill, C., Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005), 105–117, 10.1111/j.1471-4159.2004.02949.x.
116. Gupta, A., Bisht, B., Dey, C.S., Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60 (2011), 910–920, 10.1016/j.neuropharm.2011.01.033.
117. Höglinger, G.U., Rizk, P., Muriel, M.P., Duyckaerts, C., Oertel, W.H., Caille, I., Hirsch, E.C., Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7 (2004), 726–735, 10.1038/nn1265.
118. Habener, J.F., Stanojevic, V., Alpha cells come of age. Trends Endocrinol. Metab. 24 (2013), 153–163, 10.1016/j.tem.2012.10.009.
119. Halliday, G.M., Leverenz, J.B., Schneider, J.S., Adler, C.H., The neurobiological basis of cognitive impairment in Parkinson's disease. Mov. Disord. 29 (2014), 634–650, 10.1002/mds.25857.
120. Hamilton, A., Patterson, S., Porter, D., Gault, V.A., Holscher, C., Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89 (2011), 481–489, 10.1002/jnr.22565.
121. Hamza, T.H., Zabetian, C.P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D.M., Doheny, K.F., Paschall, J., Pugh, E., Kusel, V.I., Collura, R., Roberts, J., Griffith, A., Samii, A., Scott, W.K., Nutt, J., Factor, S.A., Payami, H., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42 (2010), 781–785, 10.1038/ng.642.
122. Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X.-H., Wu, M.-N., Qi, J.-S., Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. Neurobiol. Aging 34 (2013), 576–588, 10.1016/j.neurobiolaging.2012.04.009.
123. Hanyu, H., Sato, T., Kiuchi, A., Sakurai, H., Iwamoto, T., Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc. 57 (2009), 177–179, 10.1111/j.1532-5415.2009.02067.x.
124. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation, 5, 2008, 19, 10.1186/1742-2094-5-19.
125. Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., Saunders, A.M., Irizarry, M., Jeter, B., Zvartau-Hind, M., van Dyck, C.H., Gold, M., Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr. Alzheimer Res. 8 (2011), 592–606.
126. Havrankova, J., Roth, J., Brownstein, M., Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272 (1978), 827–829.
127. Havrankova, J., Schmechel, D., Roth, J., Brownstein, M., Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U. S. A. 75 (1978), 5737–5741.
128. Hely, M.A., Reid, W.G.J., Adena, M.A., Halliday, G.M., Morris, J.G.L., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23 (2008), 837–844, 10.1002/mds.21956.
129. Heneka, M.T., Fink, A., Effect of pioglitazone medication on the incidence of dementia − PubMed − NCBI [WWW Document]. Ann. Neurol., 2015 URL http://www.ncbi.nlm.nih.gov/pubmed/?term=Effect+of+pioglitazone+medication+on+the+incidence+of+dementi (accessed 7.23.15).
130. Heppner, K.M., Kirigiti, M., Secher, A., Paulsen, S.J., Buckingham, R., Pyke, C., Knudsen, L.B., Vrang, N., Grove, K.L., Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156 (2015), 255–267, 10.1210/en.2014-1675.
131. Heras-Sandoval, D., Pérez-Rojas, J.M., Hernández-Damián, J., Pedraza-Chaverri, J., The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell. Signal. 26 (2014), 2694–2701, 10.1016/j.cellsig.2014.08.019.
132. Hernandez-Baltazar, D., Mendoza-Garrido, M.E., Martinez-Fong, D., Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One, 8, 2013, e70951, 10.1371/journal.pone.0070951.
133. Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A.H., Rudolf, J., Herholz, K., Heiss, W.-D., Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62 (2005), 378–382, 10.1001/archneur.62.3.378.
134. Hill, J.M., Lesniak, M.A., Pert, C.B., Roth, J., Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17 (1986), 1127–1138.
135. Hirosumi, J., Tuncman, G., Chang, L., Görgün, C.Z., Uysal, K.T., Maeda, K., Karin, M., Hotamisligil, G.S., A central role for JNK in obesity and insulin resistance. Nature 420 (2002), 333–336, 10.1038/nature01137.
136. Hirsch, E.C., Jenner, P., Przedborski, S., Pathogenesis of parkinson's disease. Mov. Disord. 28 (2013), 24–30, 10.1002/mds.25032.
137. Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C.V., Hof, P.R., Pasinetti, G.M., Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004), 902–904, 10.1096/fj.03-0978fje.
138. Holst, J.J., Burcelin, R., Nathanson, E., Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27 (2011), 547–558, 10.1185/03007995.2010.549466.
139. Hosokai, Y., Nishio, Y., Hirayama, K., Takeda, A., Ishioka, T., Sawada, Y., Suzuki, K., Itoyama, Y., Takahashi, S., Fukuda, H., Mori, E., Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov. Disord. 24 (2009), 854–862, 10.1002/mds.22444.
140. Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., Spiegelman, B.M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996), 665–668.
141. Hoyer, S., Müller, D., Plaschke, K., (eds.) Cell and Animal Models in Aging and Dementia Research, 1994, Springer Vienna, Vienna, 10.1007/978-3-7091-9350-1.
142. Hsu, C.-C., Wahlqvist, M.L., Lee, M.-S., Tsai, H.-N., Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J. Alzheimers Dis. 24 (2011), 485–493, 10.3233/JAD-2011-101524.
143. Hsuchou, H., Kastin, A.J., Pan, W., Blood-borne metabolic factors in obesity exacerbate injury-induced gliosis. J. Mol. Neurosci. 47 (2012), 267–277, 10.1007/s12031-012-9734-4.
144. Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., Tuomilehto, J., Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007), 842–847, 10.2337/dc06-2011.
145. Huang, T.-J., Price, S.A., Chilton, L., Calcutt, N.A., Tomlinson, D.R., Verkhratsky, A., Fernyhough, P., Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 52 (2003), 2129–2136.
146. Huang, C., Mattis, P., Perrine, K., Brown, N., Dhawan, V., Eidelberg, D., Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70 (2008), 1470–1477, 10.1212/01.wnl.0000304050.05332.9c.
147. Hunot, S., Brugg, B., Ricard, D., Michel, P.P., Muriel, M.P., Ruberg, M., Faucheux, B.A., Agid, Y., Hirsch, E.C., Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 7531–7536.
148. Hunter, K., Hölscher, C., Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13, 2012, 33, 10.1186/1471-2202-13-33.
149. Hunter, R.L., Choi, D.-Y., Ross, S.A., Bing, G., Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci. Lett. 432 (2008), 198–201, 10.1016/j.neulet.2007.12.019.
150. Ibarretxe-Bilbao, N., Ramírez-Ruiz, B., Tolosa, E., Martí, M.J., Valldeoriola, F., Bargalló, N., Junqué, C., Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J. Neurol. 255 (2008), 1324–1331, 10.1007/s00415-008-0885-8.
151. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., Hashizume, Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106 (2003), 518–526, 10.1007/s00401-003-0766-2.
152. Imfeld, P., Bodmer, M., Jick, S.S., Meier, C.R., Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J. Am. Geriatr. Soc. 60 (2012), 916–921, 10.1111/j.1532-5415.2012.03916.x.
153. Irwin, D.J., Lee, V.M.-Y., Trojanowski, J.Q., Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 14 (2013), 626–636, 10.1038/nrn3549.
154. Jalewa, J., Sharma, M.K., Hölscher, C., Novel Incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells. J. Neurochem., 44, 2016, 10.1111/jnc.13736.
155. Jellinger, K.A., Seppi, K., Wenning, G.K., Poewe, W., Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J. Neural Transm. 109 (2002), 329–339.
156. Jha, S.K., Jha, N.K., Kar, R., Ambasta, R.K., Kumar, P., P38 MAPK and PI3K/AKT signalling cascades in Parkinson's disease. Int. J. Mol. Cell. Med. 4 (2015), 67–86.
157. Ji, C., Xue, G.-F., Lijun, C., Feng, P., Li, D., Li, L., Li, G., Hölscher, C., A novel dual GLPand GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res., 2015, 10.1016/j.brainres.2015.09.035.
158. Joers, V., Tansey, M.G., Mulas, G., Carta, A.R., Microglial phenotypes in Parkinson's disease and animal models of the disease. Prog. Neurobiol., 2016, 10.1016/j.pneurobio.2016.04.006.
159. Jolivalt, C.G., Lee, C.A., Beiswenger, K.K., Smith, J.L., Orlov, M., Torrance, M.A., Masliah, E., Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86 (2008), 3265–3274, 10.1002/jnr.21787.
160. Ju, T.-C., Chen, H.-M., Lin, J.-T., Chang, C.-P., Chang, W.-C., Kang, J.-J., Sun, C.-P., Tao, M.-H., Tu, P.-H., Chang, C., Dickson, D.W., Chern, Y., Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell Biol. 194 (2011), 209–227, 10.1083/jcb.201105010.
161. Ju, T.-C., Chen, H.-M., Chen, Y.-C., Chang, C.-P., Chang, C., Chern, Y., AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. Biochim. Biophys. Acta 1842 (2014), 1668–1680, 10.1016/j.bbadis.2014.06.012.
162. Jung, T.W., Lee, J.Y., Shim, W.S., Kang, E.S., Kim, S.K., Ahn, C.W., Lee, H.C., Cha, B.S., Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem. Biophys. Res. Commun. 340 (2006), 221–227, 10.1016/j.bbrc.2005.11.177.
163. Kanaan, N.M., Kordower, J.H., Collier, T.J., Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol. Aging 31 (2010), 937–952, 10.1016/j.neurobiolaging.2008.07.006.
164. Kang, M.Y., Oh, T.J., Cho, Y.M., Glucagon-Like peptide 1 increases mitochondrial biogenesis and function in INS-1 rat insulinoma cells. Endocrinol. Metab., 2014 (Seoul, Korea).
165. Kao, S.-Y., Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem. Biophys. Res. Commun. 385 (2009), 434–438, 10.1016/j.bbrc.2009.05.089.
166. Kappe, C., Tracy, L.M., Patrone, C., Iverfeldt, K., Sjöholm, Å., GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J. Neuroinflammation, 9, 2012, 276, 10.1186/1742-2094-9-276.
167. Kastin, A.J., Akerstrom, V., Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27 (2003), 313–318, 10.1038/sj.ijo.0802206.
168. Khang, R., Park, C., Shin, J.-H., Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice. Neuroscience 294 (2015), 182–192, 10.1016/j.neuroscience.2015.03.017.
169. Khasnavis, S., Jana, A., Roy, A., Mazumder, M., Bhushan, B., Wood, T., Ghosh, S., Watson, R., Pahan, K., Suppression of nuclear factor-(B activation and inflammation in microglia by physically modified saline. J. Biol. Chem. 287 (2012), 29529–29542, 10.1074/jbc.M111.338012.
170. Kieffer, T.J., McIntosh, C.H., Pederson, R.A., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995), 3585–3596, 10.1210/endo.136.8.7628397.
171. Kim, S., Moon, M., Park, S., Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202 (2009), 431–439, 10.1677/JOE-09-0132.
172. Kim, S.R., Ries, V., Cheng, H.-C., Kareva, T., Oo, T.F., Yu, W.H., Duff, K., Kholodilov, N., Burke, R.E., Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol. Dis. 44 (2011), 215–222, 10.1016/j.nbd.2011.07.003.
173. Kim, D.-H., Huh, J.-W., Jang, M., Suh, J.-H., Kim, T.-W., Park, J.-S., Yoon, S.-Y., Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiol. Dis. 46 (2012), 52–58, 10.1016/j.nbd.2011.12.043.
174. Kim, M.-H., Jee, J.-H., Park, S., Lee, M.-S., Kim, K.-W., Lee, M.-K., Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J. Endocrinol. 220 (2014), 117–128, 10.1530/JOE-13-0381.
175. Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W.R., Vienberg, S.G., Pothos, E.N., Kahn, C.R., Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. U. S. A., 2015, 10.1073/pnas.1500877112.
176. Kloet, D.E.A., Burgering, B.M.T., The PKB/FOXO switch in aging and cancer. Biochim. Biophys. Acta 1813 (2011), 1926–1937, 10.1016/j.bbamcr.2011.04.003.
177. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002), 393–403, 10.1056/NEJMoa012512.
178. Kosaraju, J., Gali, C.C., Khatwal, R.B., Dubala, A., Chinni, S., Holsinger, R.M.D., Madhunapantula, V.S.R., Muthureddy Nataraj, S.K., Basavan, D., Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 72 (2013), 291–300, 10.1016/j.neuropharm.2013.04.008.
179. Kosmalski, M., Drozdowska, A., Sliwinska, A., Drzewoski, J., Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients. Adv. Med. Sci. 57 (2012), 65–70, 10.2478/v10039-012-0017-7.
180. Kotagal, V., Albin, R.L., Müller, M.L.T.M., Koeppe, R.A., Frey, K.A., Bohnen, N.I., Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat. Disord. 19 (2013), 522–526, 10.1016/j.parkreldis.2013.01.016.
181. Kotzbauer, P.T., Cairns, N.J., Campbell, M.C., Willis, A.W., Racette, B.A., Tabbal, S.D., Perlmutter, J.S., Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch. Neurol. 69 (2012), 1326–1331.
182. Krishnamurthi, R., Stott, S., Maingay, M., Faull, R.L.M., McCarthy, D., Gluckman, P., Guan, J., N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 15 (2004), 1601–1604.
183. Kumar, N., Dey, C.S., Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. Br. J. Pharmacol. 137 (2002), 329–336, 10.1038/sj.bjp.0704878.
184. Kushner, J.A., The role of aging upon β cell turnover. J. Clin. Invest. 123 (2013), 990–995, 10.1172/JCI64095.
185. Kuwabara, T., Kagalwala, M.N., Onuma, Y., Ito, Y., Warashina, M., Terashima, K., Sanosaka, T., Nakashima, K., Gage, F.H., Asashima, M., Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 3 (2011), 742–754, 10.1002/emmm.201100177.
186. Laloux, C., Petrault, M., Lecointe, C., Devos, D., Bordet, R., Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol. Res. 65 (2012), 514–522, 10.1016/j.phrs.2012.02.008.
187. Lamm, O., Ganz, J., Melamed, E., Offen, D., Harnessing neurogenesis for the possible treatment of Parkinson's disease. J. Comp. Neurol. 522 (2014), 2817–2830, 10.1002/cne.23607.
188. LeBrasseur, N.K., Kelly, M., Tsao, T.-S., Farmer, S.R., Saha, A.K., Ruderman, N.B., Tomas, E., Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 291 (2006), E175–E181, 10.1152/ajpendo.00453.2005.
189. Leal, M.C., Fernandez Gamba, A., Morelli, L., Castaño, E.M., Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease. Med. (B. Aires). 69 (2009), 466–472.
190. Lee, C.-C., Huang, C.-C., Wu, M.-Y., Hsu, K.-S., Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J. Biol. Chem. 280 (2005), 18543–18550, 10.1074/jbc.M414112200.
191. Lee, E.Y., Lee, J.E., Park, J.H., Shin, I.C., Koh, H.C., Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. Toxicol. Lett. 213 (2012), 332–344, 10.1016/j.toxlet.2012.07.016.
192. Leonardini, A., Laviola, L., Perrini, S., Natalicchio, A., Giorgino, F., Cross-talk between PPARgamma and insulin signaling and modulation of insulin sensitivity. PPAR Res., 2009, 2009, 818945, 10.1155/2009/818945.
193. Levin, B.E., Glucose-regulated dopamine release from substantia nigra neurons. Brain Res. 874 (2000), 158–164.
194. Levy, G., Tang, M.-X., Louis, E.D., Côté, L.J., Alfaro, B., Mejia, H., Stern, Y., Marder, K., The association of incident dementia with mortality in PD. Neurology 59 (2002), 1708–1713.
195. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS 106 (2009), 1285–1290.
196. Li, J., Benashski, S.E., Venna, V.R., McCullough, L.D., Effects of metformin in experimental stroke. Stroke 41 (2010), 2645–2652, 10.1161/STROKEAHA.110.589697.
197. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., Tweedie, D., Perry, T., Mattson, M.P., Kapogiannis, D., Sambamurti, K., Lahiri, D.K., Greig, N.H., GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19 (2010), 1205–1219, 10.3233/JAD-2010-1314.
198. Li, J., Deng, J., Sheng, W., Zuo, Z., Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol. Biochem. Behav. 101 (2012), 564–574, 10.1016/j.pbb.2012.03.002.
199. Li, J., Liu, D., Sun, L., Lu, Y., Zhang, Z., Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 317 (2012), 1–5, 10.1016/j.jns.2012.02.018.
200. Li, Z., Zhou, Z., Huang, G., Hu, F., Xiang, Y., He, L., Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. PLoS One, 8, 2013, e76172, 10.1371/journal.pone.0076172.
201. Liepelt, I., Reimold, M., Maetzler, W., Godau, J., Reischl, G., Gaenslen, A., Herbst, H., Berg, D., Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov. Disord. 24 (2009), 1504–1511, 10.1002/mds.22662.
202. Liu, Y.-J., Chern, Y., AMPK-mediated regulation of neuronal metabolism and function in brain diseases. J. Neurogenet., 2015, 1–23, 10.3109/01677063.2015.1067203.
203. Liu, Z., Chai, Q., Li, Y., Shen, Q., Ma, L., Zhang, L., Wang, X., Sheng, L., Li, J., Li, J., Shen, J., Discovery of novel PTP1B inhibitors with antihyperglycemic activity. Acta Pharmacol. Sin. 31 (2010), 1005–1012, 10.1038/aps.2010.81.
204. Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., Hölscher, C., Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 303 (2015), 42–50, 10.1016/j.neuroscience.2015.06.054.
205. Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L., Hölscher, C., Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol. 765 (2015), 284–290, 10.1016/j.ejphar.2015.08.038.
206. Liu, Y.-J., Ju, T.-C., Chen, H.-M., Jang, Y.-S., Lee, L.-M., Lai, H.-L., Tai, H.-C., Fang, J.-M., Lin, Y.-L., Tu, P.-H., Chern, Y., Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 24 (2015), 787–801, 10.1093/hmg/ddu497.
207. Liu, Y.-J., Lee, L.-M., Lai, H.-L., Chern, Y., Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett. 589 (2015), 432–439, 10.1016/j.febslet.2014.12.029.
208. Long-Smith, C.M., Manning, S., McClean, P.L., Coakley, M.F., O'Halloran, D.J., Holscher, C., O'Neill, C., The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med. 15 (2013), 102–114, 10.1007/s12017-012-8199-5.
209. Lovshin, J.A., Drucker, D.J., Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5 (2009), 262–269, 10.1038/nrendo.2009.48.
210. Lu, M., Sarruf, D.A., Talukdar, S., Sharma, S., Li, P., Bandyopadhyay, G., Nalbandian, S., Fan, W., Gayen, J.R., Mahata, S.K., Webster, N.J., Schwartz, M.W., Olefsky, J.M., Brain PPAR-(promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat. Med. 17 (2011), 618–622, 10.1038/nm.2332.
211. Lu, L., Fu, D.-L., Li, H.-Q., Liu, A.-J., Li, J.-H., Zheng, G.-Q., Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One, 9, 2014, e85781, 10.1371/journal.pone.0085781.
212. Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., Klann, E., Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β. J. Neurosci. 34 (2014), 12230–12238, 10.1523/JNEUROSCI.1694-14.2014.
213. Ma, D.-L., Chen, F.-Q., Xu, W.-J., Yue, W.-Z., Yuan, G., Yang, Y., Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J. Neurochem., 2015, 10.1111/jnc.13248.
214. Maeshiba, Y., Kiyota, Y., Yamashita, K., Yoshimura, Y., Motohashi, M., Tanayama, S., Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47 (1997), 29–35.
215. Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., Polleux, F., The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron 78 (2013), 94–108, 10.1016/j.neuron.2013.02.003.
216. Malagelada, C., Jin, Z.H., Greene, L.A., RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 28 (2008), 14363–14371, 10.1523/JNEUROSCI.3928-08.2008.
217. Mandrekar-Colucci, S., Karlo, J.C., Landreth, G.E., Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 32 (2012), 10117–10128, 10.1523/JNEUROSCI.5268-11.2012.
218. Marino, J.S., Xu, Y., Hill, J.W., Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol. Metab. 22 (2011), 275–285, 10.1016/j.tem.2011.03.001.
219. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., Mucke, L., beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A 98 (2001), 12245–12250.
220. Mashayekhi, F., Mirzajani, E., Naji, M., Azari, M., Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 17 (2010), 623–627, 10.1016/j.jocn.2009.08.013.
221. Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., Sekita, A., Suzuki, S.O., Kanba, S., Kiyohara, Y., Iwaki, T., nsulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75 (2010), 764–770.
222. Matteucci, E., Giampietro, O., Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors. Curr. Med. Chem. 22 (2015), 1573–1581.
223. McClean, P.L., Gault, V.A., Harriott, P., Hölscher, C., Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630 (2010), 158–162, 10.1016/j.ejphar.2009.12.023.
224. McGovern, S.F.J., Hunter, K., Hölscher, C., Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Res. 1473 (2012), 204–213, 10.1016/j.brainres.2012.07.029.
225. McNay, E.C., Ong, C.T., McCrimmon, R.J., Cresswell, J., Bogan, J.S., Sherwin, R.S., Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem. 93 (2010), 546–553, 10.1016/j.nlm.2010.02.002.
226. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., Nagatsu, T., Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 (1994), 147–150.
227. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31 (2010), 224–243, 10.1016/j.neurobiolaging.2008.04.002.
228. Mootha, V.K., Lindgren, C.M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., Houstis, N., Daly, M.J., Patterson, N., Mesirov, J.P., Golub, T.R., Tamayo, P., Spiegelman, B., Lander, E.S., Hirschhorn, J.N., Altshuler, D., Groop, L.C., PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 (2003), 267–273, 10.1038/ng1180.
229. Moran, L.B., Graeber, M.B., Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 9 (2008), 1–13, 10.1007/s10048-007-0116-y.
230. Moran, C., Beare, R., Phan, T.G., Bruce, D.G., Callisaya, M.L., Srikanth, V., Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 85 (2015), 1123–1130, 10.1212/WNL.0000000000001982.
231. Moreira, P.I., Rolo, A.P., Sena, C., Seiça, R., Oliveira, C.R., Santos, M.S., Insulin attenuates diabetes-related mitochondrial alterations: a comparative study. Med. Chem. 2 (2006), 299–308.
232. Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G., Hirayama, K., Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 87 (1994), 343–348.
233. Morris, J.K., Zhang, H., Gupte, A.A., Bomhoff, G.L., Stanford, J.A., Geiger, P.C., Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1240 (2008), 185–195, 10.1016/j.brainres.2008.08.089.
234. Morris, J.K., Bomhoff, G.L., Stanford, J.A., Geiger, P.C., Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. AJP Regul. Integr. Comp. Physiol. 299 (2010), R1082–R1090, 10.1152/ajpregu.00449.2010.
235. Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.-P., Brooks, W.M., Gerhardt, G.A., Geiger, P.C., Stanford, J.A., Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231 (2011), 171–180, 10.1016/j.expneurol.2011.06.005.
236. Morris, J.K., Seim, N.B., Bomhoff, G.L., Geiger, P.C., Stanford, J.A., Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neurosci. Lett. 504 (2011), 219–222, 10.1016/j.neulet.2011.09.027.
237. Morris, J.K., Vidoni, E.D., Perea, R.D., Rada, R., Johnson, D.K., Lyons, K., Pahwa, R., Burns, J.M., Honea, R.A., Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience 270 (2014), 139–147, 10.1016/j.neuroscience.2014.04.006.
238. ENINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet. Neurol. 14 (2015), 795–803, 10.1016/S1474-4422(15)00144-1.
239. Nassar, N.N., Al-Shorbagy, M.Y., Arab, H.H., Abdallah, D.M., Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89 (2015), 308–317, 10.1016/j.neuropharm.2014.10.007.
240. Nath, N., Khan, M., Paintlia, M.K., Singh, I., Hoda, M.N., Giri, S., Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182 (2009), 8005–8014, 10.4049/jimmunol.0803563.
241. Ng, C.-H., Guan, M.S.H., Koh, C., Ouyang, X., Yu, F., Tan, E.-K., O'Neill, S.P., Zhang, X., Chung, J., Lim, K.-L., AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J. Neurosci. 32 (2012), 14311–143117, 10.1523/JNEUROSCI.0499-12.2012.
242. Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., Hamel, E., Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 28 (2008), 9287–9296, 10.1523/JNEUROSCI.3348-08.2008.
243. O'Keeffe, G.C., Tyers, P., Aarsland, D., Dalley, J.W., Barker, R.A., Caldwell, M.A., Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc. Natl. Acad. Sci. 106 (2009), 8754–8759, 10.1073/pnas.0803955106.
244. O'Neill, C., PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. Exp. Gerontol. 48 (2013), 647–653, 10.1016/j.exger.2013.02.025.
245. Oeckinghaus, A., Hayden, M.S., Ghosh, S., Crosstalk in NF-κB signaling pathways. Nat. Immunol. 12 (2011), 695–708, 10.1038/ni.2065.
246. Pérez-Revuelta, B.I., Hettich, M.M., Ciociaro, A., Rotermund, C., Kahle, P.J., Krauss, S., Di Monte, D.A., Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell. Death. Dis., 5, 2014, e1209, 10.1038/cddis.2014.175.
247. Palacios, N., Gao, X., McCullough, M.L., Jacobs, E.J., Patel, A.V., Mayo, T., Schwarzschild, M.A., Ascherio, A., Obesity, diabetes, and risk of Parkinson's disease. Mov. Disord. 26 (2011), 2253–2259, 10.1002/mds.23855.
248. Pan, P.L., Shi, H.C., Zhong, J.G., Xiao, P.R., Shen, Y., Wu, L.J., Song, Y.Y., He, G.X., Li, H.L., Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies. Neurol. Sci. 34 (2013), 613–619, 10.1007/s10072-012-1250-3.
249. Papadopoulos, P., Rosa-Neto, P., Rochford, J., Hamel, E., Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology. PLoS One, 8, 2013, e68612, 10.1371/journal.pone.0068612.
250. Park, C.R., Seeley, R.J., Craft, S., Woods, S.C., Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 68 (2000), 509–514.
251. Patil, S.P., Jain, P.D., Ghumatkar, P.J., Tambe, R., Sathaye, S., Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 277 (2014), 747–754, 10.1016/j.neuroscience.2014.07.046.
252. Pawlikowska, L., Hu, D., Huntsman, S., Sung, A., Chu, C., Chen, J., Joyner, A.H., Schork, N.J., Hsueh, W.-C., Reiner, A.P., Psaty, B.M., Atzmon, G., Barzilai, N., Cummings, S.R., Browner, W.S., Kwok, P.-Y., Ziv, E., Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 8 (2009), 460–472, 10.1111/j.1474-9726.2009.00493.x.
253. Peppard, R.F., Martin, W.R., Carr, G.D., Grochowski, E., Schulzer, M., Guttman, M., McGeer, P.L., Phillips, A.G., Tsui, J.K., Calne, D.B., Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch. Neurol. 49 (1992), 1262–1268.
254. Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10 (2014), 143–156, 10.1038/nrendo.2013.256.
255. Perruolo, G., Viggiano, D., Fiory, F., Cassese, A., Nigro, C., Liotti, A., Miele, C., Beguinot, F., Formisano, P., Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice. Sci. Rep., 6, 2016, 29967, 10.1038/srep29967.
256. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T.Y., Egan, J.M., Greig, N.H., A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300 (2002), 958–966.
257. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., Greig, N.H., Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72 (2003), 603–612, 10.1002/jnr.10611.
258. Perry, V.H., Cunningham, C., Holmes, C., Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7 (2007), 161–617, 10.1038/nri2015.
259. Picardi, P.K., Calegari, V.C., Prada, P.O., Prada, P., de, O., Moraes, J.C., Araújo, E., Marcondes, M.C.C.G., Ueno, M., Carvalheira, J.B.C., Velloso, L.A., Saad, M.J.A., Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats. Endocrinology 149 (2008), 3870–3880, 10.1210/en.2007-1506.
260. Picconi, B., Piccoli, G., Calabresi, P., Synaptic dysfunction in Parkinson's disease. Adv. Exp. Med. Biol. 970 (2012), 553–572, 10.1007/978-3-7091-0932-8_24.
261. Pocai, A., Unraveling oxyntomodulin, GLP1’s enigmatic brother. J. Endocrinol. 215 (2012), 335–346, 10.1530/JOE-12-0368.
262. Porter, D.W., Kerr, B.D., Flatt, P.R., Holscher, C., Gault, V.A., Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes. Obes. Metab. 12 (2010), 891–899, 10.1111/j.1463-1326.2010.01259.x.
263. Qin, Z., Pandey, N.R., Zhou, X., Stewart, C.A., Hari, A., Huang, H., Stewart, A.F.R., Brunel, J.M., Chen, H.-H., Functional properties of Claramine: a novel PTP1 B inhibitor and insulin-mimetic compound. Biochem. Biophys. Res. Commun. 458 (2015), 21–27, 10.1016/j.bbrc.2015.01.040.
264. Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y.P., Cheng, Y., Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol., 2016, 10.1001/jamaneurol.2016.2742.
265. Qiu, W.Q., Folstein, M.F., Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006), 190–198, 10.1016/j.neurobiolaging.2005.01.004.
266. Quinn, L.P., Crook, B., Hows, M.E., Vidgeon-Hart, M., Chapman, H., Upton, N., Medhurst, A.D., Virley, D.J., The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 154 (2008), 226–233, 10.1038/bjp.2008.78.
267. Ramos-Rodriguez, J.J., Molina-Gil, S., Ortiz-Barajas, O., Jimenez-Palomares, M., Perdomo, G., Cozar-Castellano, I., Lechuga-Sancho, A.M., Garcia-Alloza, M., Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models. PLoS One, 9, 2014, e89229, 10.1371/journal.pone.0089229.
268. Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., Whitton, P.S., Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46 (2012), 183–193, 10.1016/j.npep.2012.07.004.
269. Reagan, L.P., Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp. Neurol. 233 (2012), 68–78, 10.1016/j.expneurol.2011.02.004.
270. Reale, M., Greig, N.H., Kamal, M.A., Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev. Med. Chem. 9 (2009), 1229–1241.
271. Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., Onofrj, M., Peripheral cytokines profile in Parkinson's disease. Brain. Behav. Immun. 23 (2009), 55–63, 10.1016/j.bbi.2008.07.003.
272. Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C.E., Ben-Shlomo, Y., Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane database Syst. Rev. CD008454., 2011, 10.1002/14651858 CD008454. pub2.
273. Regensburger, M., Prots, I., Winner, B., Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity. Neural Plast., 2014, 2014, 454696, 10.1155/2014/454696.
274. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Cherrier, M.M., Schellenberg, G.D., Frey, W.H., Craft, S., Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimers Dis. 13 (2008), 323–331.
275. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Breitner, J.C.S., DeGroodt, W., Mehta, P., Craft, S., Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008), 440–448, 10.1212/01.WNL.0000265401.62434.36.
276. Ribeiro, C.A., Silva, A.M., Viana, S.D., Pereira, F.C., Sitagliptin does not protect against MPTP-induced dopaminergic striatal toxicity. 6th European Congress of Pharmacology (EPHAR 2012), 2012.
277. Risner, M.E., Saunders, A.M., Altman, J.F.B., Ormandy, G.C., Craft, S., Foley, I.M., Zvartau-Hind, M.E., Hosford, D.A., Roses, A.D., Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246–54. http://dx.doi.org/10.1038/sj.tpj.6500369.
278. Rodriguez-Rivera, J., Denner, L., Dineley, K.T., Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 216 (2011), 255–261, 10.1016/j.bbr.2010.08.002.
279. Rosenthal, E., Brennan, L., Xie, S., Hurtig, H., Milber, J., Weintraub, D., Karlawish, J., Siderowf, A., Association between cognition and function in patients with Parkinson disease with and without dementia. Mov. Disord. 25 (2010), 1170–1176, 10.1002/mds.23073.
280. Ruderman, N.B., Carling, D., Prentki, M., Cacicedo, J.M., AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123 (2013), 2764–2772, 10.1172/JCI67227.
281. Sadeghian, M., Marinova-Mutafchieva, L., Broom, L., Davis, J.B., Virley, D., Medhurst, A.D., Dexter, D.T., Full and partial peroxisome proliferation-activated receptor-(agonists, but not (agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J. Neuroimmunol. 246 (2012), 69–77, 10.1016/j.jneuroim.2012.03.010.
282. Sakr, H.F., Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J. Physiol. Pharmacol. 64 (2013), 613–623.
283. Salminen, A., Kaarniranta, K., AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res. Rev. 11 (2012), 230–241, 10.1016/j.arr.2011.12.005.
284. Sandyk, R., The relationship between diabetes mellitus and Parkinson's disease. Int. J. Neurosci. 69 (1993), 125–130.
285. Sankar, R., Thamotharan, S., Shin, D., Moley, K.H., Devaskar, S.U., Insulin-responsive glucose transporters-GLUT8 and GLUT4 are expressed in the developing mammalian brain. Brain Res. Mol. Brain Res. 107 (2002), 157–165.
286. Santiago, J.A., Potashkin, J.A., System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol. Dis, 2014, 10.1016/j.nbd.2014.03.019.
287. Santos, Fernando, R., Diamond-Stanic, H.E., Contribution of the serine kinase c-Jun N-terminal kinase (JNK) to oxidant-induced insulin resistance in isolated rat skeletal muscle [WWW Document]. Arch. Physiol. Biochem., 2012 URL http://informahealthcare.com/doi/pdf/10.3109/13813455.2012.713366 (accessed 4.21.15).
288. Sastre, M., Dewachter, I., Landreth, G.E., Willson, T.M., Klockgether, T., van Leuven, F., Heneka, M.T., Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003), 9796–9804.
289. Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., Iwamoto, T., Efficacy of PPAR-(agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 32 (2011), 1626–1633, 10.1016/j.neurobiolaging.2009.10.009.
290. Savica, R., Grossardt, B.R., Ahlskog, J.E., Rocca, W.A., Metabolic markers or conditions preceding Parkinson's disease: a case-control study. Mov. Disord. 27 (2012), 974–979, 10.1002/mds.25016.
291. Schapira, A.H.V., Tolosa, E., Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6 (2010), 309–317, 10.1038/nrneurol.2010.52.
292. Schapira, A.H.V., Olanow, C.W., Greenamyre, J.T., Bezard, E., Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, 6736, 2014, 10.1016/S0140-6736(14)61010-2.
293. Schapira, A.H.V., Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7 (2008), 97–109, 10.1016/S1474-4422(07)70327-7.
294. Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., Ritz, B., Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34 (2011), 1102–1108, 10.2337/dc10-1333.
295. Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E.C.A., PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease− PubMed − NCBI [WWW Document]. Eur. J. Neurosci., 2009 URL http://www.ncbi.nlm.nih.gov/pubmed/19245367?dopt=Abstract (accessed 7.23.15).
296. Schroll, H., Vitay, J., Hamker, F.H., Dysfunctional and compensatory synaptic plasticity in Parkinson's disease. Eur. J. Neurosci. 39 (2014), 688–702, 10.1111/ejn.12434.
297. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., Arndt, S., Jacobs, A.H., Krone, W., Kahn, C.R., Brüning, J.C., Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 3100–3105, 10.1073/pnas.0308724101.
298. Sekiyama, K., Sugama, S., Fujita, M., Sekigawa, A., Takamatsu, Y., Waragai, M., Takenouchi, T., Hashimoto, M., Neuroinflammation in Parkinson's disease and related disorders: a lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis., 271732, 2012, 10.1155/2012/271732.
299. Selman, C., Lingard, S., Choudhury, A.I., Batterham, R.L., Claret, M., Clements, M., Ramadani, F., Okkenhaug, K., Schuster, E., Blanc, E., Piper, M.D., Al-Qassab, H., Speakman, J.R., Carmignac, D., Robinson, I.C.A., Thornton, J.M., Gems, D., Partridge, L., Withers, D.J., Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 22 (2008), 807–818, 10.1096/fj.07-9261com.
300. Shannon, R.P., DPP-4 inhibition and neuroprotection: do mechanisms matter?. Diabetes 62 (2013), 1029–1031, 10.2337/db12-1794.
301. Sharma, A.N., Elased, K.M., Lucot, J.B., Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. J. Psychopharmacol. 26 (2012), 724–732, 10.1177/0269881111434620.
302. Sharma, S.K., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., Wittung-Stafshede, P., Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci. Rep., 5, 2015, 12531, 10.1038/srep12531.
303. Shemesh, E., Rudich, A., Harman-Boehm, I., Cukierman-Yaffe, T., Effect of intranasal insulin on cognitive function: a systematic review. J. Clin. Endocrinol. Metab. 97 (2012), 366–376, 10.1210/jc.2011-1802.
304. Shibata, N., Yamamoto, T., Hiroi, A., Omi, Y., Kato, Y., Kobayashi, M., Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 30 (2010), 353–360, 10.1111/j.1440-1789.2009.01078.x.
305. Soccio, R.E., Chen, E.R., Lazar, M.A., Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 20 (2014), 573–591, 10.1016/j.cmet.2014.08.005.
306. Spielman, L.J., Little, J.P., Klegeris, A., Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol., 2014, 10.1016/j.jneuroim.2014.06.004.
307. Steculorum, S.M., Solas, M., Brüning, J.C., The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimers Dement. 10 (2014), S3–S11, 10.1016/j.jalz.2013.12.008.
308. Steneberg, P., Bernardo, L., Edfalk, S., Lundberg, L., Backlund, F., Ostenson, C.-G., Edlund, H., The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Diabetes 62 (2013), 2004–2014, 10.2337/db12-1045.
309. Stoica, L., Zhu, P.J., Huang, W., Zhou, H., Kozma, S.C., Costa-Mattioli, M., Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 3791–3796, 10.1073/pnas.1014715108.
310. Sudoh, S., Frosch, M.P., Wolf, B.A., Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and −insoluble pools in CHO-695 cells. Biochemistry 41 (2002), 1091–1099.
311. Sun, X., Huang, L., Zhang, M., Sun, S., Wu, Y., Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. Toxicology 271 (2010), 5–12, 10.1016/j.tox.2010.01.001.
312. Sun, Y., Chang, Y.-H., Chen, H.-F., Su, Y.-H., Su, H.-F., Li, C.-Y., Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35 (2012), 1047–1049, 10.2337/dc11-1511.
313. Suzuki, S., Arnold, L.L., Pennington, K.L., Kakiuchi-Kiyota, S., Wei, M., Wanibuchi, H., Cohen, S.M., Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 113 (2010), 349–357, 10.1093/toxsci/kfp256.
314. Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendic, S., Ludvigsson, J.F., Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov. Disord, 2016, 10.1002/mds.26734.
315. Swanson, C., Emborg, M., Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol. Res. 36 (2014), 634–646, 10.1179/1743132813Y.0000000305.
316. Swanson, C.R., Joers, V., Bondarenko, V., Brunner, K., Simmons, H.A., Ziegler, T.E., Kemnitz, J.W., Johnson, J.A., Emborg, M.E., The PPAR-(agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation, 8, 2011, 91, 10.1186/1742-2094-8-91.
317. Taguchi, A., Wartschow, L.M., White, M.F., Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317 (2007), 369–372, 10.1126/science.1142179.
318. Tain, L.S., Mortiboys, H., Tao, R.N., Ziviani, E., Bandmann, O., Whitworth, A.J., Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12 (2009), 1129–1135, 10.1038/nn.2372.
319. Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., Okada, H., Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci. Lett. 204 (1996), 201–204, 10.1016/0304-3940(96)12357-0.
320. Talbot, K., Wang, H.-Y., The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers. Dement. 10 (2014), S12–S25, 10.1016/j.jalz.2013.12.007.
321. Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122 (2012), 1316–1338, 10.1172/JCI59903.
322. Thouennon, E., Cheng, Y., Falahatian, V., Cawley, N.X., Loh, Y.P., Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J. Neurochem. 134 (2015), 463–470, 10.1111/jnc.13152.
323. Timmons, S., Coakley, M.F., Moloney, A.M., O’ Neill, C., Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 467 (2009), 30–35, 10.1016/j.neulet.2009.09.055.
324. Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., Ikeuchi, T., Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J. Biol. Chem. 287 (2012), 35222–35233, 10.1074/jbc.M112.348300.
325. Tolosa, E., Gaig, C., Santamaría, J., Compta, Y., Diagnosis and the premotor phase of Parkinson disease. Neurology 72 (2009), S12–S20, 10.1212/WNL.0b013e318198db11.
326. Tong, M., Dong, M., de la Monte, S.M., Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J. Alzheimers. Dis. 16 (2009), 585–599, 10.3233/JAD-2009-0995.
327. Torres-Aleman, I., Toward a comprehensive neurobiology of IGF-I. Dev. Neurobiol. 70 (2010), 384–396, 10.1002/dneu.20778.
328. Vekrellis, K., Ye, Z., Qiu, W.Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M.R., Selkoe, D.J., Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000), 1657–1665.
329. Wahlqvist, M.L., Lee, M.-S., Hsu, C.-C., Chuang, S.-Y., Lee, J.-T., Tsai, H.-N., Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat. Disord. 18 (2012), 753–758, 10.1016/j.parkreldis.2012.03.010.
330. Wang, X.H., Li, L., Hölscher, C., Pan, Y.F., Chen, X.R., Qi, J.S., Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170 (2010), 1239–1248, 10.1016/j.neuroscience.2010.08.028.
331. Wang, X.-J., Zhang, S., Yan, Z.-Q., Zhao, Y.-X., Zhou, H.-Y., Wang, Y., Lu, G.-Q., Zhang, J.-D., Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic. Biol. Med. 50 (2011), 1094–1106, 10.1016/j.freeradbiomed.2011.01.032.
332. Wang, L., Zhai, Y.-Q., Xu, L.-L., Qiao, C., Sun, X.-L., Ding, J.-H., Lu, M., Hu, G., Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 251 (2014), 22–29, 10.1016/j.expneurol.2013.11.001.
333. Wang, S., Zhang, C., Sheng, X., Zhang, X., Wang, B., Zhang, G., Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases. J. Clin. Neurosci. 21 (2014), 810–814, 10.1016/j.jocn.2013.08.017.
334. Watson, G.S., Cholerton, B.A., Reger, M.A., Baker, L.D., Plymate, S.R., Asthana, S., Fishel, M.A., Kulstad, J.J., Green, P.S., Cook, D.G., Kahn, S.E., Keeling, M.L., Craft, S., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005), 950–958, 10.1176/appi.ajgp.13.11.950.
335. Willette, A.A., Xu, G., Johnson, S.C., Birdsill, A.C., Jonaitis, E.M., Sager, M.A., Hermann, B.P., La Rue, A., Asthana, S., Bendlin, B.B., Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 36 (2013), 443–449, 10.2337/dc12-0922.
336. Willette, A.A., Bendlin, B.B., Starks, E.J., Birdsill, A.C., Johnson, S.C., Christian, B.T., Okonkwo, O.C., La Rue, A., Hermann, B.P., Koscik, R.L., Jonaitis, E.M., Sager, M.A., Asthana, S., Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol., 2015, 10.1001/jamaneurol.2015.0613.
337. Willette, A.A., Johnson, S.C., Birdsill, A.C., Sager, M.A., Christian, B., Baker, L.D., Craft, S., Oh, J., Statz, E., Hermann, B.P., Jonaitis, E.M., Koscik, R.L., La Rue, A., Asthana, S., Bendlin, B.B., Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 11 (2015), 504–510, 10.1016/j.jalz.2014.03.011 e1.
338. Williams-Gray, C.H., Evans, J.R., Goris, A., Foltynie, T., Ban, M., Robbins, T.W., Brayne, C., Kolachana, B.S., Weinberger, D.R., Sawcer, S.J., Barker, R.A., The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132 (2009), 2958–2969, 10.1093/brain/awp245.
339. Williams-Gray, C.H., Mason, S.L., Evans, J.R., Foltynie, T., Brayne, C., Robbins, T.W., Barker, R.A., The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J. Neurol. Neurosurg. Psychiatry 84 (2013), 1258–1264, 10.1136/jnnp-2013-305277.
340. Williams-Gray, C.H., Wijeyekoon, R., Yarnall, A.J., Lawson, R.A., Breen, D.P., Evans, J.R., Cummins, G.A., Duncan, G.W., Khoo, T.K., Burn, D.J., Barker, R.A., ICICLE-PD study group, Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov. Disord. 31 (2016), 995–1003.
341. Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N., Sidhu, A., Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 225 (2010), 210–218, 10.1016/j.expneurol.2010.06.017.
342. Xiromerisiou, G., Hadjigeorgiou, G.M., Papadimitriou, A., Katsarogiannis, E., Gourbali, V., Singleton, A.B., Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 436 (2008), 232–234, 10.1016/j.neulet.2008.03.026.
343. Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., Chen, H., Diabetes and risk of Parkinson's disease. Diabetes Care 34 (2011), 910–915, 10.2337/dc10-1922.
344. Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., Liu, L., Zhang, H., Xu, C., Zhou, Q., Huang, S., Chen, L., Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in vitro models of Parkinson's disease. Cell. Signal. 26 (2014), 1680–1689, 10.1016/j.cellsig.2014.04.009.
345. Yamada, N., Katsuura, G., Ochi, Y., Ebihara, K., Kusakabe, T., Hosoda, K., Nakao, K., Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 152 (2011), 2634–2643, 10.1210/en.2011-0004.
346. Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M.P., Heneka, M.T., PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 32 (2012), 17321–17331, 10.1523/JNEUROSCI.1569-12.2012.
347. Yao, W.-D., Gainetdinov, R.R., Arbuckle, M.I., Sotnikova, T.D., Cyr, M., Beaulieu, J.-M., Torres, G.E., Grant, S.G.N., Caron, M.G., Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41 (2004), 625–638.
348. Yong, S.W., Yoon, J.K., An, Y.S., Lee, P.H., A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur. J. Neurol. 14 (2007), 1357–1362, 10.1111/j.1468-1331.2007.01977.x.
349. Yuan, Y.-H., Yan, W.-F., Sun, J.-D., Huang, J.-Y., Mu, Z., Chen, N.-H., The molecular mechanism of rotenone-induced α-synuclein aggregation: emphasizing the role of the calcium/GSK3β pathway. Toxicol. Lett. 233 (2015), 163–171, 10.1016/j.toxlet.2014.11.029.
350. Zhang, F., Qian, L., Flood, P.M., Shi, J.-S., Hong, J.-S., Gao, H.-M., Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J. Pharmacol. Exp. Ther. 333 (2010), 822–833, 10.1124/jpet.110.165829.
351. Zhang, H., Hao, Y., Manor, B., Novak, P., Milberg, W., Zhang, J., Fang, J., Novak, V., Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes 64 (2015), 1025–1034, 10.2337/db14-1000.
352. Zhao, W.-Q., Townsend, M., Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792 (2009), 482–496, 10.1016/j.bbadis.2008.10.014.
353. Zhao, L., Teter, B., Morihara, T., Lim, G.P., Ambegaokar, S.S., Ubeda, O.J., Frautschy, S.A., Cole, G.M., Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 24 (2004), 11120–11126, 10.1523/JNEUROSCI.2860-04.2004.
354. Zhao, W.-Q., Chen, H., Quon, M.J., Alkon, D.L., Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490 (2004), 71–81, 10.1016/j.ejphar.2004.02.045.
355. Zheng, B., Liao, Z., Locascio, J.J., Lesniak, K.A., Roderick, S.S., Watt, M.L., Eklund, A.C., Zhang-James, Y., Kim, P.D., Hauser, M.A., Grünblatt, E., Moran, L.B., Mandel, S.A., Riederer, P., Miller, R.M., Federoff, H.J., Wüllner, U., Papapetropoulos, S., Youdim, M.B., Cantuti-Castelvetri, I., Young, A.B., Vance, J.M., Davis, R.L., Hedreen, J.C., Adler, C.H., Beach, T.G., Graeber, M.B., Middleton, F.A., Rochet, J.-C., Scherzer, C.R., PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med., 2, 2010, 10.1126/scitranslmed.3001059 52ra73.
356. Zick, Y., Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol. 11 (2001), 437–441.
357. de Lau, L.M.L., Breteler, M.M.B., Epidemiology of Parkinson's disease. Lancet. Neurol. 5 (2006), 525–535, 10.1016/S1474-4422(06)70471-9.
358. van Heemst, D., Beekman, M., Mooijaart, S.P., Heijmans, B.T., Brandt, B.W., Zwaan, B.J., Slagboom, P.E., Westendorp, R.G.J., Reduced insulin/IGF-1 signalling and human longevity. Aging Cell, 2005, 79–85, 10.1111/j.1474-9728.2005.00148.x.
359. van der Heide, L.P., Ramakers, G.M.J., Smidt, M.P., Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 79 (2006), 205–221, 10.1016/j.pneurobio.2006.06.003.